NCT00635414View on ClinicalTrials.gov

Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

October 31, 2002

Study Completion Date

October 31, 2002

Conditions
GERD
Interventions
DRUG

Esomeprazole

40mg oral

DRUG

Esomeprazole

15 minute intravenous infusion

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00635414 - Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously | Biotech Hunter | Biotech Hunter